EUVIMEDEUVIMED entdecken
Crossref

In vitro and ex vivo Pharmacological Profile of HY-022619, a Novel Intravenous P2Y12 Receptor Antagonist with Rapid-onset and Sustained Antiplatelet Activity

Jiajia Mo, Emily M He, Yan Zhao, Li Shao, Shaoyun Yue, Yanmei Xie, Shiqi Wu, Jianxun He, Yi Zou, Zhaoxing Chu, Guangwei He, Yungen Xu

Pharmaceutical Research · 2026

DOI: 10.1007/s11095-026-04092-6 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceutical Research, 2026. Verfasst von Jiajia Mo und 11 weiteren Autor:innen. Beteiligte Einrichtung: Jiangsu Key Laboratory of Drug Design and Optimization, Department of Medicinal Chemistry, China Pharmaceutical University, Nanjing, 211198, China. Hauptthemen laut MEDLINE: Purinergic P2Y Receptor Antagonists, Receptors, Purinergic P2Y12, Platelet Aggregation Inhibitors, Adenosine. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 50 Literaturangaben. Gefördert von: Anhui Provincial Key Research and Development Program of Traditional Chinese Medicine.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Patients with acute coronary syndrome (ACS) require rapid and potent antiplatelet therapy during percutaneous coronary intervention (PCI). Current first-line P2Y₁₂ inhibitors are limited by delayed efficacy or an ultrashort half-life. This study aims to characterize the metabolism and pharmacodynamics of HY-022619, a disodium phosphate ester salt of ticagrelor, to provide a theoretical basis for its clinical use in peri-PCI antithrombotic therapy. METHODS: The inhibitory activity of HY-022619 against the P2Y₁₂ receptor and ADP-induced platelet aggregation was evaluated in vitro. Molecular docking was performed to compare its receptor-binding mode with ticagrelor. Metabolic stability was assessed in whole blood, liver microsomes, and using recombinant enzymes. Pharmacodynamic profiles were investigated in rats and beagle dogs, with additional assessments of metabolic conversion and bleeding time in dogs. RESULTS: HY-022619 showed 22-fold greater P2Y₁₂ receptor inhibition and 15-fold stronger suppression of platelet aggregation than ticagrelor. Molecular docking revealed that enhanced activity was due to an additional salt bridge. HY-022619 remained stable in human and non-rodent whole blood (half-life > 60 min) and was primarily hydrolysed to ticagrelor in the liver by CES1 and CES2. In rats, intravenous administration produced rapid, dose-dependent platelet inhibition within 5 min. In dogs, HY-022619 acted rapidly with efficacy peaking at the end of infusion. It converted completely to ticagrelor within 5 min post-infusion, maintaining antiplatelet effects for 6 h, without significantly prolonging bleeding time compared to ticagrelor. CONCLUSION: HY-022619 demonstrates rapid, potent, and sustained antiplatelet effects, supporting its potential clinical application.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Purinergic P2Y Receptor AntagonistsReceptors, Purinergic P2Y12Platelet Aggregation InhibitorsAdenosineAnimalsDogsHumansMaleRatsPlatelet AggregationRats, Sprague-DawleyMicrosomes, LiverMolecular Docking SimulationTicagrelor

Stichwörter der Autor:innen

HY-022619P2Y 12antagonistacute coronary syndromeantiplatelet therapypercutaneous coronary intervention

Substanzen

Purinergic P2Y Receptor AntagonistsReceptors, Purinergic P2Y12Platelet Aggregation InhibitorsTicagrelorAdenosine

Autor:innen und Institutionen

  • Jiangsu Key Laboratory of Drug Design and Optimization, Department of Medicinal Chemistry, China Pharmaceutical University, Nanjing, 211198, China.
  • Hefei Institute of Pharmaceutical Industry Co., Ltd., Hefei, 230601, China.
  • Stanford University School of Medicine, Stanford, CA, 94305, USA.
  • Hefei Institute of Pharmaceutical Industry Co., Ltd., Hefei, 230601, China. chuzhaoxing@163.com.
  • Hefei Institute of Pharmaceutical Industry Co., Ltd., Hefei, 230601, China. heguangwei@ahipi.com.
  • Jiangsu Key Laboratory of Drug Design and Optimization, Department of Medicinal Chemistry, China Pharmaceutical University, Nanjing, 211198, China. xyg@cpu.edu.cn.

Förderung

  • Anhui Provincial Key Research and Development Program of Traditional Chinese Medicine

Zitieren

APA

Mo, J., He, E. M., Zhao, Y., Shao, L., Yue, S., Xie, Y., Wu, S., He, J., Zou, Y., Chu, Z., He, G., & Xu, Y. (2026). In vitro and ex vivo Pharmacological Profile of HY-022619, a Novel Intravenous P2Y12 Receptor Antagonist with Rapid-onset and Sustained Antiplatelet Activity. Pharmaceutical Research. https://doi.org/10.1007/s11095-026-04092-6

Vancouver

Mo J, He EM, Zhao Y, Shao L, Yue S, Xie Y, et al. In vitro and ex vivo Pharmacological Profile of HY-022619, a Novel Intravenous P2Y12 Receptor Antagonist with Rapid-onset and Sustained Antiplatelet Activity. Pharmaceutical Research. 2026. doi:10.1007/s11095-026-04092-6

BibTeX
@article{Mo2026,
  author = {Mo, Jiajia and He, Emily M and Zhao, Yan and Shao, Li and Yue, Shaoyun and Xie, Yanmei and Wu, Shiqi and He, Jianxun and Zou, Yi and Chu, Zhaoxing and He, Guangwei and Xu, Yungen},
  title = {In vitro and ex vivo Pharmacological Profile of HY-022619, a Novel Intravenous P2Y12 Receptor Antagonist with Rapid-onset and Sustained Antiplatelet Activity},
  journal = {Pharmaceutical Research},
  year = {2026},
  doi = {10.1007/s11095-026-04092-6}
}
Kostenlos starten →